Skip to main content

Q3/Q1-3 2022 Results

Fresenius with weak third quarter driven by ongoing challenging macroeconomic environment – FY/22 guidance revised – Charting a new course for Fresenius

 

  • Healthy organic sales growth and ongoing margin pressure

  • Fresenius Medical Care’s business development impacted by delayed effects from improvements in North American Services business in challenging environment

  • Fresenius Kabi with healthy sales growth and sequential improvement 

  • Fresenius Helios with strong organic sales growth, solid EBIT in line with usual third quarter seasonality

  • Fresenius Vamed impacted by macroeconomic headwinds and COVID-19

Selected Key Figures Q1-3/2022

SALES

30197 m

+ 4% 1

Q1-3/21: €27,554 m

EBIT 2

2952 m

-10% 1

Q1-3/21: €3,086 m

NET INCOME 2, 3

1284 m

-8% 1, 4

Q1-3/21: €1,346 m

EARNINGS PER SHARE 2, 3

2.29 m

-10% 1

Q1-3/21: €2.41

1 In constant currency

2 Before special items

3 Net income attributable to shareholders of Fresenius SE & Co. KGaA

4 Excluding Ivenix acquisition

Sales by business segment

€ in millions Q1-3/22 Q1-3/21 ChangeGrowth at constant ratesOrganic growthAcquisitionsDivestitures% of total sales1

Fresenius Medical Care

14,40112,97215%2%1%1%0%47%

Fresenius Kabi

5,8145,3708%2%2%0%0%19%

Fresenius Helios

8,6858,0098%8%6%2%0%29%

Fresenius Vamed

1,6471,5496%6%6%1%-1%5%

Total

30,19727,55410%4%3%1%0%100%

  • 1 Related to the respective external sales of the business segments. Consolidation effects and corporate entities are not taken into account. Therefore, aggregation to total Group sales is not possible.

Archive